Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation

Journal of Pineal Research

Volumn 60, Issue 1, 2016, Pages 27-38

  Ju, Huai Qiang ^a   Li, Hao ^a   Tian, Tian ^a   Lu, Yun Xin ^a   Bai, Long ^a   Chen, Le Zong ^a   Sheng, Hui ^a   Mo, Hai Yu ^a   Zeng, Jun Bo ^a   Deng, Wuguo ^a   Chiao, Paul J ^b   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chemoresistance; gemcitabine; melatonin; nuclear factor B; pancreatic cancer

Indexed keywords

BETA ACTIN; CHEMOKINE RECEPTOR CXCR4; CYCLIN D1; GELATINASE A; GELATINASE B; GEMCITABINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMIN A; MELATONIN; PROTEIN BCL XL; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN C; DEOXYCYTIDINE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL INVASION; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MELATONIN; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; NF-KAPPA B; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955196115     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12285     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Singh D, Upadhyay G, Srivastava RK, et al., Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochim Biophys Acta 2015; 1856: 13-27.
3. di Magliano MP, Logsdon CD,. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220-1229.
4. Wang P, Sun YC, Lu WH, et al., Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase. Chin J Cancer 2015; 34: 166-176.
5. Collins MA, Bednar F, Zhang Y, et al., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122: 639-653.
6. Ying H, Kimmelman AC, Lyssiotis CA, et al., Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-670.
7. Yang J, Splittgerber R, Yull FE, et al., Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest 2010; 120: 2563-2574.
8. Ling J, Kang Y, Zhao R, et al., KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 105-120.
9. Wang W, Abbruzzese JL, Evans DB, et al., The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
10. Karin M, Lin A,. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
11. Brown M, Cohen J, Arun P, et al., NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 2008; 12: 1109-1122.
12. Arora S, Bhardwaj A, Singh S, et al., An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J Biol Chem 2013; 288: 21197-21207.
13. Gocho T, Uwagawa T, Furukawa K, et al., Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-kappaB activation for pancreatic cancer. Cancer Lett 2013; 333: 89-95.
14. Melisi D, Xia Q, Paradiso G, et al., Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 2011; 103: 1190-1204.
15. Claustrat B, Leston J,. Melatonin: physiological effects in humans. Neurochirurgie 2015; 61: 77-84.
16. Carocci A, Catalano A, Sinicropi MS,. Melatonergic drugs in development. Clin Pharmacol 2014; 6: 127-137.
17. Singh M, Jadhav HR,. Melatonin: functions and ligands. Drug Discov Today 2014; 19: 1410-1418.
18. Calvo JR, Gonzalez-Yanes C, Maldonado MD,. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013; 55: 103-120.
19. Reiter RJ, Tan DX, Fuentes-Broto L,. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-151.
20. Wang J, Guo W, Chen W, et al., Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res 2013; 54: 406-416.
21. Li Z, Nickkholgh A, Yi X, et al., Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-κB and apoptosis after experimental kidney transplantation. J Pineal Res 2009; 46: 365-372.
22. Xiang S, Dauchy RT, Hauch A, et al., Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res 2015; 59: 60-69.
23. Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, et al., Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res 2014; 56: 20-30.
24. Xu C, Wu A, Zhu H, et al., Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance. Biomed Pharmacother 2013; 67: 133-139.
25. Bao B, Ali S, Kong D, et al., Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6: e17850.
26. Chang Z, Li Z, Wang X, et al., Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res 2013; 19: 549-559.
27. Chang Z, Ju H, Ling J, et al., Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One 2014; 9: e101452.
28. Ju HQ, Gocho T, Aguilar M, et al., Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol Cancer Ther 2015; 14: 788-798.
29. Didonato JA, Mercurio F, Karin M,. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400.
30. Shi D, Xiao X, Wang J, et al., Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-kappaB, c/EBPbeta, and p300 signaling. J Pineal Res 2012; 53: 154-165.
31. Wang Z, Li Y, Ahmad A, et al., Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
32. Fujioka S, Sclabas GM, Schmidt C, et al., Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003; 22: 1365-1370.
33. Wang DS, Chen DL, Ren C, et al., ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer 2012; 131: 461-468.
34. Colbert LE, Hall WA, Nickleach D, et al., Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014; 120: 499-506.
35. Burris HA 3rd, Moore MJ, Andersen J, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
36. Koay EJ, Truty MJ, Cristini V, et al., Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014; 124: 1525-1536.
37. Olive KP, Jacobetz MA, Davidson CJ, et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
38. Holcomb BK, Yip-Schneider MT, Waters JA, et al., Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg 2012; 16: 1333-1340.
39. Fuchs O,. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets 2013; 13: 16-34.
40. Balistreri CR, Candore G, Accardi G, et al., NF-kappaB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies. Immun Ageing 2013; 10: 24.
41. Tornatore L, Sandomenico A, Raimondo D, et al., Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta/MKK7 inhibitors. Cancer Cell 2014; 26: 495-508.